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Background: Conjugate vaccines, such as the 7-valent conjugate vaccine (PCV7), alter serotype nasopharyngeal
carriage, potentially increasing cases of otitis media by non-vaccine serotypes.
Methods: All paediatric middle ear fluid (MEF) isolates received in the Spanish Reference Laboratory for
Pneumococci through a passive, laboratory-based surveillance system from January 1997 to June 2009 were
analysed. Data from 1997 to 2000 were pooled as pre-vaccination period. Trends over time were explored by linear
regression analysis.
Results: A total of 2,077 isolates were analysed: 855 belonging to PCV7 serotypes, 466 to serotype 19A, 215 to
serotype 3, 89 to serotype 6A and 452 to other serotypes (< 40 isolates each). Over time, there has been a
decreasing trend for PCV7 serotypes (R
2 = 0.944; p < 0.001, with significant decreasing trends for serotypes 19F, 14,
23F and 9V), and increasing trends for serotype 19A (R
2 = 0.901; p < 0.001), serotype 3 (R
2 = 0.463; p = 0.030) and
other non-PCV7 serotypes (R
2 = 0.877; p < 0.001), but not for serotype 6A (R
2 = 0.311; p = 0.094). Considering all
isolates, amoxicillin non-susceptibility showed an increasing trend (R
2 = 0.528; p = 0.017). Regarding serotype 19A,
increasing trends in non-susceptibility to penicillin (R
2 = 0.726; p = 0.001), amoxicillin (R
2 = 0.804; p < 0.001),
cefotaxime (R
2 = 0.546; p = 0.005) and erythromycin (R
2 = 0.546; p = 0.009) were found, with amoxicillin non-
susceptibility firstly detected in 2003 (7.4%) and increasing up to 38.0% in 2009. In PCV7 serotypes (which
prevalence decreased from 70.7% during 1997-2000 to 10.6% in 2009) amoxicillin non-susceptibility rates showed
an increasing trend (R
2 = 0.702; p = 0.002). However, overall, amoxicillin non-susceptibility (≈25% in 2008-9) could
be mainly attributed to serotype 19A (> 35% isolates) since PCV7 strains represented < 11% of total clinical isolates.
Conclusions: In contrast to reports on invasive pneumococcal strains, in MEF isolates the reduction in the
prevalence of PCV7 serotypes was not associated with decreases in penicillin/erythromycin non-susceptibility. The
high prevalence of serotype 19A among paediatric MEF isolates and the amoxicillin non-susceptibility found in this
serotype are worrisome since amoxicillin is the most common antibiotic used in the treatment of acute otitis
media. These data suggest that non-PCV7 serotypes (mainly serotype 19A followed by serotypes 3 and 6A) are
important etiological agents of acute otitis media and support the added value of the broader coverage of the
new 13-valent conjugate vaccine.
Keywords: Susceptibility, serotype 19A, middle ear isolates, non-susceptibility time trends, surveillance
* Correspondence: laguilar@med.ucm.es
2Microbiology Dept., School of Medicine, Univ. Complutense, Avda.
Complutense s/n, 28040 Madrid, Spain
Full list of author information is available at the end of the article
Fenoll et al. BMC Infectious Diseases 2011, 11:239
http://www.biomedcentral.com/1471-2334/11/239
© 2011 Fenoll et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Acute otitis media (AOM) is the most common infec-
tion in children following pneumococcal colonization of
the upper respiratory tract [1], and the most common
reason for which antibiotics are prescribed in children
[2]. Streptococcus pneumoniae is worldwide identified in
30-60% cases of AOM [3,4]. In recent decades the emer-
gence of pneumococcal strains exhibiting non-suscept-
ibility to penicillin, especially in middle ear fluid isolates
[5-7], has evolved into a global problem because non-
susceptibility to penicillin is associated with decreases in
the intrinsic activity of other oral b-lactams.
Among the 93 pneumococcal serotypes [8], the seven
most commonly found in the US causing invasive dis-
ease in children are targeted by the 7-valent pneumo-
coccal conjugate vaccine (PCV7) [9]. PCV7 is available
in Spain (approx. 45 million inhabitants) since October
2001, but only in the private market for children under
2 years of age, with a vaccination schedule of 2-, 4-, 6-
month primary series plus a fourth dose at 15-18
months. Although the vaccine use increased from 2002
onwards, the reported vaccine coverage in 2006 was
below 50% (assuming complete vaccination schedules)
[10]. In October 2006, the Autonomous Region of
Madrid (approx. 6 million inhabitants) approved its
inclusion in the childhood vaccination calendar with the
vaccination schedule stated above. Despite the irregular
regional PCV7 uptake in Spain, vaccination has resulted
in a decrease in PCV7 serotypes among invasive isolates
from children and adults (due to herd effect). This
reduction has been associated with a decrease in the
proportion of isolates non-susceptible to penicillin
[11-13]. However, as in other countries, these changes
were associated with an increase in the prevalence of
non-PCV7 serotypes causing invasive disease [11].
Conjugate vaccines protect against nasopharyngeal
carriage of serotypes included in the vaccine [14]. This
ecological niche can then be filled by other serotypes
[15], with subsequent potential increases in otitis media
by non-vaccine serotypes [14,16].
This study focuses on pneumococcal isolates from
middle ear fluid received in the Spanish Reference
Laboratory for Pneumococci (SRLP) from hospitals
located all over Spain, and analyses changes in serotype
distribution and antibiotic susceptibility in the period
1997-2009.
Methods
All paediatric (≤ 14 years of age) S. pneumoniae isolates
from middle ear fluid received in the SRLP from hospi-
tals located all over the 17 Autonomous Regions in
Spain from January 1997 to June 2009 were analysed.
Isolates had been sent on a voluntary basis through a
passive, laboratory-based surveillance system. All MEF
isolates in global and the subgroups of PCV7 and 19A
isolates were distributed per age group (< 2 years, 2-4
years and 5-14 years). Data from 1997 to 2000 were
pooled as pre-vaccination period. Isolates were sero-
typed by Quellung reaction [17] and/or Dot blot assay
[18]. Susceptibility to penicillin, amoxicillin, cefotaxime
and erythromycin was determined by agar dilution using
Mueller-Hinton agar (Difco Laboratories, Detroit, MI,
USA) supplemented with 5% sheep blood (Biomedics,
Madrid, Spain) as culture media. Plates were incubated
under 5% CO2 atmosphere as recommended by the
Clinical and Laboratory Standards Institute [19]. S.
pneumoniae ATCC 6303 and S. pneumoniae ATCC
49619 plus six clinical isolates were used as quality con-
trols [20]. Current non-susceptibility breakpoints for
oral penicillin (MIC ≥ 0.12 μg/ml), amoxicillin (MIC ≥ 4
μg/ml), cefotaxime (MIC ≥ 2 μg/ml; non-meningitis)
and erythromycin (MIC ≥ 0.5 μg/ml) [19] were
considered.
Trends along time (1997-2000 to 2009) of serotype
prevalence and non-susceptibility rates were explored by
regression analysis (SPSS v14 programme, SPSS Inc,
Chicago IL) with time as independent variable. Linear
regression analysis was used, based on highest goodness
of fit.
Results
Table 1 shows the annual total number of paediatric
pneumococcal isolates received in the SRLP from Janu-
ary 1997 to June 2009, and the number (and percentage)
of paediatric isolates from middle ear fluid. As shown,
no great variations in the annual percentage of isolates
from middle ear fluid among all paediatric isolates
received in the SRLP were found over time. Of the
2,077 middle ear fluid isolates from children ≤ 14 years
of age received in the study period (481 from the period
1997-2000 and 1,596 from 2001 on), 855 isolates
belonged to PCV7 serotypes, 466 to serotype 19A, 215
to serotype 3, 89 to serotype 6A and 452 to other sero-
types (with < 40 isolates each). Table 1 also shows the
annual distribution per age group (< 2 years, 2-4 years
and 5-14 years) of total MEF isolates, and PCV7 and
19A isolates among them. Significant (p < 0.001)
decreasing trends (R
2 ≥ 0.851) were found for the
pooled PCV7 serotypes in the three age groups, with b
ranging from -0.923 to -0.952. In contrast, significant
increasing trends were found for serotype 19A mainly in
the < 2 years age group (R
2 = 0.940; b = 0.969; p <
0.001) and, to a lesser extent, in the 2-4 years group (R
2
=0 . 6 3 3 ;b = 0.796; p < 0.006), but not in the 5-14 years
group.
Figure 1 shows percentages over time of all middle ear
isolates distributed by serotype including PCV7 pooled
serotypes, serotypes 19A,3 ,6 Aa n do t h e rg r o u p e d
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Page 2 of 8Table 1 Annual total number of paediatric isolates (invasive + non-invasive) received by the SRLP, total no. (%) of
paediatric middle ear fluid isolates (MEF), and among them, no. (%) of PCV7 and 19A isolates
97-00 2001 2002 2003 2004 2005 2006 2007 2008 2009
Total no. 2342 758 874 802 1196 1374 1136 1326 1291 749
MEF [n (%)] 481 (20.5) 210 (27.7) 171 (19.6) 159 (19.8) 180 (15.1) 166 (12.1) 176 (15.5) 173 (13.0) 220 (17.0) 141 (18.8)
< 2 yrs. 253 (52.6) 121 (57.6) 81(47.4) 69 (43.4) 81 (45.0) 91 (54.8) 97 (55.1) 95 (54.9) 153 (69.5) 86 (61.0)
2-4 yrs. 68 (14.1) 43 (20.5) 49 (28.7) 34 (21.4) 46 (25.6) 26 (15.7) 50 (28.4) 51 (29.5) 44 (20.0) 35 (24.8)
5-14 yrs. 160 (33.3) 46 (21.9) 41 (24.0) 56 (35.2) 53 (29.4) 49 (29.5) 29 (16.5) 27 (15.6) 23 (10.5) 20 (14.2)
PCV-7 [n (%)]* 340 (70.7) 132 (62.9) 109 (63.7) 77 (48.4) 64 (35.6) 40 (24.1) 33 (18.8) 23 (13.3) 22 (10.0) 15 (10.6)
< 2 yrs. 186 (54.7) 86 (65.2) 59 (54.1) 37 (48.1) 35 (54.7) 23 (57.5) 11 (33.3) 10 (43.5) 15 (68.2) 10 (66.7)
2-4 yrs. 54 (15.9) 20 (15.2) 30 (27.5) 13 (16.9) 16 (25.0) 7 (17.5) 12 (36.4) 10 (43.5) 5 (22.7) 2 (13.3)
5-14 yrs. 100 (29.4) 26 (19.7) 20 (18.3) 27 (35.1) 13 (20.3) 10 (25.0) 10 (30.3) 3 (13.0) 2 (9.1) 3 (20.0)
19A [n (%)]* 32 (6.7) 20 (9.5) 21 (12.3) 27 (17.0) 38 (21.1) 53 (31.9) 55 (31.3) 67 (38.7) 103 (46.8) 50 (35.5)
< 2 yrs. 18 (56.3) 14 (70.0) 9 (42.9) 14 (51.9) 20 (52.6) 35 (66.0) 41 (74.5) 48 (71.6) 80 (77.7) 42 (84.0)
2-4 yrs. 3 (9.4) 3 (15.0) 4 (19.0) 6 (22.2) 7 (18.4) 5 (9.4) 10 (18.2) 11 (16.4) 19 (18.4) 7 (14.0)
5-14 yrs. 11 (34.4) 3 (15.0) 8 (38.1) 7 (25.9) 11 (28.9) 13 (24.5) 4 (7.3) 8 (11.9) 4 (3.9) 1 (2.0)
Distribution [no. (%)] per-age group (< 2 years, 2-4 years and 5-14 years) of total MEF isolates and of PCV-7 and 19A isolates among them.
*Percentages among MEF isolates
Figure 1 Annual prevalence of isolates belonging to PCV7 serotypes (as a group), serotype 19A, serotype 3, serotype 6A and other
grouped non-PCV7 serotypes.
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Page 3 of 8serotypes. Our results show a significant decreasing
trend for PCV7 serotypes (R
2 = 0.944; b = -0.972; p <
0.001), and significant increasing trends for serotype
19A (R
2 = 0.901; b = 0.949; p < 0.001) and, to a lesser
extent, for serotype 3 (R
2 = 0.463; b = 0.681; p = 0.030).
No significant trend was found for serotype 6A (R
2 =
0.311; b = -0.558; p = 0.094). In addition, other pooled
non-PCV7 serotypes (39 serotypes in total) exhibited a
significant increasing trend (R
2 =0 . 8 0 6b =0 . 8 9 8 ;p<
0.001).
Figure 2 shows the percentages of isolates belonging
to serotypes included in PCV7 over time. Significant
decreasing trends were found for serotypes 19F (322 iso-
lates; R
2 = 0.875; b = -0.943; p < 0.001), 6B (138 isolates;
R
2 = 0.801; b = -0.907; p < 0.001), 14 (203 isolates; R
2 =
0.729; b = -0.871; p = 0.001), 23F (93 isolates; R
2 =
0.719; b = -0.866; p = 0.001) and 9V (42 isolates; R
2 =
0.559; b = -0.779; p = 0.008). Serotypes 18C (31 isolates)
and 4 (9 isolates) did not show significant trends (R
2 ≤
0.114; b ≤ -0.393; p ≥ 0.180), probably due to the small
number of isolates.
Regarding non-susceptibility, only PCV7 serotypes (as
a group) and serotypes 19A and 3 had more than 10
isolates per year and could be analysed in separate. Ser-
otype 3 was fully susceptible to penicillin, amoxicillin
and cefotaxime over the study period, with non-suscept-
ibility rates to erythromycin < 10% from 2005 on.
Table 2 shows annual non-susceptibility rates in all
middle ear fluid isolates and in the subgroups of 19A
and PCV7 isolates. Considering all middle ear fluid iso-
lates, no significant trends were found for non-suscept-
ibility to penicillin (R
2 = 0.219; b = -0.468; p = 0.172) or
erythromycin (R
2 =0 . 1 4 5 ;b = -0.381; p = 0.277), with
non-susceptibility rates in the range of 36.7% to 58.5%
for both antibiotics in the period 2001-2009. Moreover,
non-susceptibility rates to cefotaxime were ≤ 8.5% along
the study period, showing no trends (R
2 =0 . 1 4 2 ;b =
0.377; p = 0.238). However, non-susceptibility to amoxi-
cillin showed a significant increasing trend (R
2 = 0.528;
b =0 . 7 2 7 ;p=0 . 0 1 7 ) ,w i t hn o n - s u s c e p t i b i l i t yr a t e s
within the range 6.0% to 8.8% in 2001-5, 10.8% to 19.0%
in 2006-7, and 24.1% to 25.0% in 2008-9.
Figure 2 Annual prevalence of isolates belonging to serotypes included in PCV7.
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over the study period), increasing trends were found for
non-susceptibility to penicillin (R
2 = 0.726; b =0 . 8 7 0 ;p
= 0.001), amoxicillin (R
2 = 0.804; b = 0.909; p < 0.001),
cefotaxime (R
2 = 0.546; b =0 . 7 7 2 ;p=0 . 0 0 5 )a n de r y -
thromycin (R
2 = 0.546; b = 0.772; p = 0.009). Non-sus-
ceptibility rates to penicillin and erythromycin were
around 80% in 2008-2009. Non-susceptibility to amoxi-
cillin was first detected in 2003 and increased up to
38.0% in 2009. Non-susceptibility to cefotaxime was
found in a single strain in 1999 whereas in the period
2001-2009 was firstly detected in 2004 and increased up
to 20.0% in 2009.
When analyzing non-susceptibility rates in PCV7 sero-
types (for which the prevalence decreased over the study
period), no trends were found for penicillin (R
2 =0 . 1 0 6 ;
b = -0.130; p = 0.721) with non-susceptibility rates of ≥
67.5%, neither for erythromycin (R
2 =0 . 2 8 3 ;b = -0.602;
p = 0.065) with non-susceptibility rates of ≥ 36.4%, nor
for cefotaxime (R
2 = 0.120; b = 0.067; p = 0.854) with
non-susceptibility rates of ≤ 12.5% over the studied per-
iod. In contrast, there was a significant increasing trend
for non-susceptibility to amoxicillin (R
2 = 0.702; b =
0.858; p = 0.002), with rates around 50% in 2008-9. The
individual analysis of PCV7 serotypes to determine sero-
type(s) responsible(s) for this increasing trend, showed
that there was a non-susceptibility increasing trend for
serotypes 19F (332 isolates; R
2 = 0.517; b = 0.755; p =
0.012), 6B (138 isolates; R
2 =0 . 6 9 0 ;b =0 . 8 5 1 ;p=
0.002), and 9V (49 isolates; R
2 = 0.379; b = 0.669; p =
0.034), but not for serotypes 14 (203 isolates), 23F (93
isolates) and 4 (9 isolates). Isolates belonging to serotype
18C (31 isolates) were fully susceptible to amoxicillin.
Considering multiple resistance as a concomitant non-
susceptibility event to b-lactams (using cefotaxime as
marker) and erythromycin in a single isolate, the per-
centage of isolates exhibiting multiple resistance was >
10% in serotype 19A, with rates ranging from 11.7% to
20.0% in the 2007-2009 period.
Discussion
Data from the United States at the time of PCV7 licen-
sure showed that the vaccine (including the most com-
mon invasive and often drug-resistant serotypes causing
disease in children) provided 89.1% protective efficacy
against invasive disease caused by all serotypes [21]. In a
post-introduction surveillance study the percentage of
reduction in invasive disease caused by PCV7 serotypes
was 78%, with 50% reduction in invasive disease caused
by vaccine-related serotypes [22]. However, serotype
replacement has been reported in surveillances (labora-
tory-based surveillance system) analyzing invasive iso-
lates along the current decade in Spain [11-13], USA
[23] and several European countries [24]. In addition,
several studies have shown that PCV7 vaccination also
reduces the nasopharyngeal carriage of vaccine serotypes
and increases carriage of non-vaccine types, with an
overall rate of pneumococcal colonization unchanged in
most cases [25-28]. AOM is the most common infection
following pneumococcal colonization. Since PCV7 intro-
duction, 57%-66.7% reduction in otitis media episodes
caused by PCV7 serotypes has been reported with an
Table 2 Number of paediatric middle ear fluid isolates (MEF), and among them, number of PCV-7 and 19A isolates,
with per-group percentages of non-susceptibility to penicillin (PEN), amoxicillin (AMX), cefotaxime (CTX), and
erythromycin (ERY)
97-00 2001 2002 2003 2004 2005 2006 2007 2008 2009
MEF (n) 481 210 171 159 180 166 176 173 220 141
PEN 69.0 58.1 58.5 42.8 36.7 45.8 41.5 47.4 53.2 51.1
AMX - 8.1 8.8 8.2 6.7 6.0 10.8 19.0 25.0 24.1
CTX 5.2 4.8 4.1 1.9 6.1 1.8 1.1 6.9 6.8 8.5
ERY 55.3 51.0 51.5 45.3 42.8 48.8 49.4 48.6 52.7 44.7
PCV-7 (n) 340 132 109 77 64 40 33 23 22 15
PEN 88.5 82.6 83.5 67.5 68.7 77.5 69.7 73.9 81.8 86.7
AMX - 12.1 13.8 13.0 17.2 15.0 21.2 26.1 50.0 53.3
CTX 6.5 7.6 6.4 3.9 12.5 2.5 3.0 8.7 9.1 6.7
ERY 65.0 57.6 63.3 58.4 64.1 67.5 63.6 43.5 36.4 53.2
19A (n) 32 20 21 27 38 53 55 67 103 50
PEN 50.0 40.0 23.8 44.4 47.4 62.3 67.3 70.1 80.6 84.0
AMX - 0.0 0.0 7.4 2.6 5.7 21.8 38.8 37.9 38.0
CTX 3.1 0.0 0.0 0.0 7.9 3.8 1.8 14.9 11.7 20.0
ERY 50.0 65.0 33.3 59.3 68.4 79.2 78.2 82.1 85.4 76.0
Non-susceptibility: PEN ≥ 0.12 μg/ml; AMX ≥ 4 μg/ml; CTX ≥ 2 μg/ml; ERY ≥ 0.5 μg/ml
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in clinical trials [21,29] and post-introduction surveil-
lances [30,31]. However the possible decrease in PCV7
serotypes among middle ear fluid isolates after the intro-
duction of the PCV7 in Spain, remained to be explored.
The present study showed that serotype replacement
has occurred among middle ear isolates from children
in Spain as demonstrated by the decrease in PCV7 sero-
types (from 62.9% in 2001 to 10.6% in 2009) and the
increase in the prevalence of serotype 19A (from 6.7%
in 1997-00 to > 35% from 2007 on) and to a lesser
extent of serotype 3 (already described as an emergent
serotype due to replacement [32]).
In a previous study analysing invasive isolates from
children, one important fact of the significant decrease
in the prevalence of PCV7 serotypes (from 62.4% in
2000 to 14.6% in 2007) was that the reduction was fol-
lowed by a significant decreasei nn o n - s u s c e p t i b i l i t yt o
penicillin and erythromycin (from 51.4% and 39.5%,
respectively, to around 20% for both antibiotics in 2007)
[12]. In contrast to this, the main finding of the present
study is that in middle ear fluid isolates from children
the significant decrease in PCV7 serotypes after PCV7
introduction was not associated with a decrease in non-
susceptibility to penicillin or erythromycin among mid-
dle ear fluid isolates. High non-susceptibility rates (≈40-
50%) to these two antibiotic markers were found all
over the study period among all middle ear fluid iso-
lates. Even more, a significant increase in amoxicillin
non-susceptibility (from 8.1% in 2001 to ≈25% in 2008
and 2009) was found. By analysing the two major sub-
groups (serotype 19A and non-PCV7 serotypes), it can
be deduced that this increase was mainly attributed to
the significant increase in the prevalence of serotype
19A. In this serotype, it is important to remark that the
first middle ear isolates non-susceptible to amoxicillin
were detected in 2003, and proportions increased up to
≈38% in the period 2007-9, as occurred with non-sus-
ceptibility to cefotaxime that in the present decade was
first detected in 2004 and reached 20% in 2009. Non-
susceptibility to these two b-lactams and to erythromy-
cin (multiple resistance) was found in > 10% of 19A iso-
lates in the last years of the decade. This multiresistance
pattern, challenging common therapeutic options, has
also been described after vaccine introduction in USA in
serotype 19A middle ear fluid isolates from children
[33].
However, in our study, amoxicillin non-susceptibility
cannot be entirely attributed to serotype 19A or other
non-PCV7 serotypes since the significant decrease in
PCV7 serotypes was associated with a significant
increase in amoxicillin non-susceptibility among them,
clustered in PCV7 serotypes 19F, 6B and 9V. The fact
that these serotypes exhibited a significant decreasing
trend over the study period suggests that these serotypes
(and thus non-susceptibility to amoxicillin) will further
decrease as vaccination rates increase. Nevertheless, the
contribution of PCV7 serotypes to the prevalence of
amoxicillin non-susceptibility among all middle ear iso-
lates is relatively low since, although amoxicillin non-
susceptibility in PCV7 isolates was ≈50% in 2008-9, all
PCV7 isolates represented only ≈10% of all middle ear
isolates received in the SRLP. The high antibiotic con-
sumption for the treatment of AOM (the most common
infection for which antibiotics are prescribed in children
in the community [2]) represents the major pressure for
resistance selection [11]. This antibiotic pressure over
the selectable residual occurrence of PCV7 serotypes
(probably due to low vaccine coverage) may be a reason
for the lack of reduction in resistance in parallel to the
reduction in the prevalence of PCV7 serotypes (in con-
trast to invasive isolates). In this sense a previous study
showed that S. pneumoniae is more often resistant to
antibiotics in otitis prone children [31], and consump-
tion of aminopenicillins is by far greater than consump-
tion of macrolides in Spain [11].
As stated, data of this study came from a passive
laboratory-based surveillance system with strains sent
on a voluntary basis from hospitals all over the Spanish
geography. Although the high number of isolates ana-
lysed over the large study period and its geographic
diversity strengthen conclusions about serotypes
involved in otitis in Spain, three main limitations of the
study may be identified: 1) isolates were sent by micro-
biology departments in hospitals, and the SRLP does not
have clinical information on the type of otitis or on how
samples were collected, 2) isolates came from hospitals,
thus they are not necessarily representative of pneumo-
cocci causing otitis in children attending primary care
centres and 3) multilocus sequence typing was not per-
formed, thus specific sequence types responsible for the
increase in 19A cannot be identified, as was done for
paediatric invasive isolates in a previous study highlight-
ing the outstanding role of sequence types 320 and 878
(first detected in 2003 and 2007, respectively) [34].
Conclusions
The high prevalence of serotype 19A among paediatric
middle ear isolates and the high rates of amoxicillin
non-susceptibility found in this serotype are of great
concern since amoxicillin is the most common antibiotic
used in the treatment of AOM. These data suggest that
non-PCV7 serotypes (mainly serotype 19A followed by
serotypes 3 and 6A) are important etiological agents of
AOM and support the added value of the broader cov-
erage of the new 13-valent conjugate vaccine. Reducing
nasopharyngeal carriage (and subsequently preventing
AOM) of vaccine serotypes may be an added value in a
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Page 6 of 8context where it has been postulated that the reduction
in drug-resistant S. pneumoniae will require a combina-
tion of conjugate vaccine and reductions in antibiotic
use [28].
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